Seeking Alpha

Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an...

Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an Overweight rating on shares with a $25 price target, following Goldman Sachs adding the firm to its Conviction Buy List yesterday. Shares are down 1.4%, standing as the leader for Dow components on the day.
Comments (5)
  • InvestorCP
    , contributor
    Comments (155) | Send Message
     
    They must have destroyed that drum by now. Its been beaten up over the last decade on and off. I do not see where there is organic growth here, its all by acquisition. Their dividend is a good reward for someone looking for income, but if you want to be defensive, corporate bonds and preferred stocks are worth a look. You can actually get a decent return on them for income. PFE's stock price is stuck in the mud. I guess I do not understand why you would put money in PFE.
    10 Aug 2011, 12:26 PM Reply Like
  • CWulf
    , contributor
    Comments (6) | Send Message
     
    If everybody is buying, who is selling?
    10 Aug 2011, 12:40 PM Reply Like
  • mitrado
    , contributor
    Comments (1957) | Send Message
     
    If everybody is selling, who is buying?
    10 Aug 2011, 01:25 PM Reply Like
  • CWulf
    , contributor
    Comments (6) | Send Message
     
    Searching for donJuan
    10 Aug 2011, 12:41 PM Reply Like
  • Liz R
    , contributor
    Comments (11) | Send Message
     
    Yah I don't know why anyone would want to invest in a drug company that has decided to cut back so sharply on research and development in favor of short term profits. Maybe Pfizer thinks stock buybacks will somehow cause the Tooth Fairy to leave new ready-to-test drugs under its pillow some night.
    10 Aug 2011, 12:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|